

References

- **Abdel-Rahman, E, Bolton, WK.** Pimagedine: a novel therapy for diabetic nephropathy. *Expert Opin Investig Drugs* 2002; 11:565.
- **Adler, AI, Stevens, RJ, Manley, SE, Bilous, RW.** Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 2003; 63:225.
- **Adler, AI, Stratton, IM, Neil, HA, et al.** Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ* 2000; 321:412.
- **Adler, S.** Diabetic nephropathy: Linking histology, cell biology, and genetics. *Kidney Int* 2004; 66:2095.
- **Agarwal, R.** Statin induced proteinuria: renal injury or renoprotection?. *J Am Soc Nephrol* 2004; 15:2502.
- **Ahmed, SB, Hovind, P, Parving, HH, et al.** Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. *Diabetes Care* 2005; 28:1988.
- **Akahori, H, Ota, T, Torita, M, et al.** Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. *J Pharmacol Exp Ther* 2005; 314:51
- **Alaveras, AE, Thomas, SM, Sagriotis, A, Viberti, GC.** Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. *Nephrol Dial Transplant* 1997; 12 Suppl 2:71.
- **Alsheikh-Ali, AA, Ambrose, MS, Kuvin, JT, Karas, RH.** The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. *Circulation* 2005; 111:3051.
- **Alvestrand, A.** Carbohydrate and insulin metabolism in renal failure. *Kidney Int* 1997; 52(Suppl 62):S48.

- **Ansari, A, Thomas, S, Goldsmith, D.** Assessing glycemic control in patients with diabetes and end-stage renal failure. *Am J Kidney Dis 2003; 41:523.*
- **Ansquer, JC, Foucher, C, Rattier, S, et al.** Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). *Am J Kidney Dis 2005;45:485.*
- **Araki, S, Haneda, M, Sugimoto, T, et al.** Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. *Diabetes 2005; 54:2983.*
- **Araki, S, Ng, DP, Krolewski, B, et al.** Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-beta1 (PRKCB1) gene locus. *J Am Soc Nephrol 2003; 14:2015.*
- **Atkins, RC, Briganti, EM, Lewis, JB, et al.** Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. *Am J Kidney Dis 2005; 45:281.*
- **Atkins, RC, Briganti, EM, Lewis, JB, et al.** Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. *Am J Kidney Dis 2005; 45:281.*
- **Atthobari, J, Brantsma, AH, Gansevoort, RT, et al.** The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. *Nephrol Dial Transplant 2006; 21:3106*
- **Babaei-Jadidi, R, Karachalias, N, Ahmed, N, et al.** Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. *Diabetes 2003; 52:2110.*
- **Bakris, GL, Barnhill, BW, Sadler, R.** Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. *Kidney Int 1992; 41:91*
- **Bakris, GL, Copley, JB, Vicknair, N, et al.** Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. *Kidney Int 1996; 50:1641.*

- **Bakris, GL, Ruilope, LM, McMorn, SO, et al.** Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. *J Hypertens* 2006; 24:2047.
- **Bakris, GL, Siomos M, Richardson, D, et al.** ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. *Kidney Int* 2000; 58:2084.
- **Bakris, GL, Weir, MR, Dequattro, V, McMahon, FG.** Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. *Kidney Int* 1998; 54:1283.
- **Bakris, GL, Weir, MR, Shanifar, S, Zhang, Z.** Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. *Arch Intern Med* 2003; 163:1555.
- **Bakris, GL, Weir, MR.** Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link?. *Am J Hypertens* 1996; 9:200S.
- **Barbosa, J, Steffes, MW, Sutherland, DER, et al.** Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. *J Am Med Assoc* 1994; 272:600.
- **Barnett, AH, Bain, SC, Bouter, P, et al.** Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med* 2004; 351:1952.
- **Basta, G, DeCaterina, R.** Products of advanced glycosylation and the pathogenesis of accelerated atherosclerosis in diabetes. *G Ital Cardiol* 1996; 26:699.
- **Becker, BN, Odorico, JS, Becker, YT, et al.** Simultaneous pancreas-kidney and pancreas transplantation. *J Am Soc Nephrol* 2001; 12:2517.
- **Benigni, A, Gagliardini, E, Tomasoni, S, et al.** Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. *Kidney Int* 2004; 65:2193.
- **Benigni, A, Perico, N, Remuzzi, G.** The potential of endothelin antagonism as a therapeutic approach. *Expert Opin Investig Drugs* 2004; 13:1419.

- **Benigni, A, Zoja, C, Corna, D, Zatelli, C.** Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. *J Am Soc Nephrol* 2003; 14:1816.
- **Benigni, A, Zoja, C, Tomasoni, S, et al.** Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor- γ agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. *J Am Soc Nephrol* 2006; 17:1624.
- **Berl, T, Hunsicker, LG, Lewis, JB, et al.** Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. *J Am Soc Nephrol* 2005; 16:2170.
- **Biesenbach, G, Zazgornik, J.** Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. *Diabetes Care* 1996; 19:625.
Howard, BV, Howard, WJ. The compelling case for smoking cessation in diabetics. *Circulation* 1990; 82:299.
- **Bilous, RW, Mauer, SM, Sutherland, DE, et al.** The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. *N Engl J Med* 1989; 321:80.
- **Birch, KA, Heath, WF, Hermeling, RN, et al.** LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element. *Diabetes* 1996; 45:642.
- **Bohlen, L, de Courten, M, Weidmann, P.** Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. *Am J Hypertens* 1994; 7:84S.
- **Bojestig, M, Arnqvist, HJ, Hermansson, G, et al.** Declining incidence of nephropathy in insulin-dependent diabetes mellitus. *N Engl J Med* 1994; 330:15.
- **Bonegio, RG, Fuhro, R, Wang, Z, et al.** Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. *J Am Soc Nephrol* 2005; 16:2063.
- **Boright, AP, Paterson, AD, Mirea, L, et al.** Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe

nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 2005; 54:1238.

- **Brancati, FL, Whittle, JC, Whelton, PK, et al.** The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. JAMA 1992; 268:3079.
- **Brenner, BM, Cooper, ME, de Zeeuw, D, et al.** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861.
- **Breyer, JA.** Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992; 20:533.
- **Brodsky, IG, Robbins, DC, Hiser, E, et al.** Effects of low-protein diets on protein metabolism in insulin-dependent diabetes mellitus patients with early nephropathy. J Clin Endocrinol Metab 1992; 75:351.
- **Brownlee, M.** Pharmacological modulation of the advanced glycosylation reaction. Prog Clin Biol Res 1989; 304:235.
- **Brownlee, M, Vlassara, H, Kooney, T, et al.** Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232:1629.
- **Bryk, R, Wolff, DJ.** Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N⁶-(1-iminoethyl)lysine. Biochemistry 1998; 37:4844.
- **Bucala, R, Makita, Z, Vega, G, et al.** Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994; 91:9441.
- **Burns, WC, Twigg, SM, Forbes, JM, et al.** Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006; 17:2484.
- **Cameron, NE, Cotter, MA.** Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative

stress and essential fatty acid dysmetabolism. *Diabetes Metab Res Rev* 2002; 18:315.

- **Chaiken, RL, Palmisano, J, Norton, ME, et al.** The interaction of hypertension and diabetes on renal function in black NIDDM subjects. *Kidney Int* 1995; 47:1697.
- **Chang, JW, Yang, WS, Min WK, et al.** Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. *Am J Kidney Dis* 2002; 39:1213
- **Chantrel, F, Enache, I, Bouiller, M, et al.** Abysmal prognosis of patients with type 2 diabetes entering dialysis. *Nephrol Dial Transplant* 1999; 14:129.
- **Chaturvedi, N, Stephenson, JM, Fuller, JH, and the EURODIAB IDDM Complications Study Group.** The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. *Diabetes Care* 1995; 18:785.
- **Chen, S, Cohen, MP, Lautenslager, GT, et al.** Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. *Kidney Int* 2001; 59:799.
- **Cooper, ME.** Pathogenesis, prevention, and treatment of diabetic nephropathy. *Lancet* 1998; 352:213.
- **Corbett, JA, Tilton, RG, Chang, K.** Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. *Diabetes* 1992; 41:552.
- **Corman, B, Duriez, M, Poitevin, P, et al.** Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. *Proc Natl Acad Sci U S A* 1998; 95:1301.
- **Cottrell, DA, Henry, ML, O'Dorisio, TM, et al.** Hypoglycemia after successful pancreas transplantation in type 1 diabetic patients (letter). *Diabetes Care* 1991; 14:1111.
- **Cowell, RM, Russell, JW.** Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy. *J Investig Med* 2004; 52:33.

- **Cowie, CC, Port, FK, Wolfe, RA, et al.** Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. *N Engl J Med* 1989; 321:1074.
- **Craven, PA, DeRubertis, FR.** Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: Possible mediation by glucose. *J Clin Invest* 1989; 87:31.
- **Dahl-Jorgensen, K, Bjoro, T, Kierulf, P, et al.** Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus. *Kidney Int* 1992; 41:920.
- **Dai, C, Yang, J, Bastacky, S, et al.** Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. *J Am Soc Nephrol* 2004; 15:2637.
- **Daneman, D, Crompton, CH, Balfe, JW, et al.** Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. *Kidney Int* 1994; 46:1154.
- **Daneman, D.** Type 1 diabetes. *Lancet* 2006; 367:847.
- **Davis, BJ, Forbes, JM, Thomas, MC, et al.** Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. *Diabetologia* 2004; 47:89.
- **de Zeeuw, D, Remuzzi, G, Parving, HH, et al.** Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 2004; 110:921.
- **Dhein, S, Hochreuther, S, Aus Dem, Spring C, Bollig, K.** Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. *J Pharmacol Exp Ther* 2000; 293:351.
- **Diaz-Buxo, JA.** Blood glucose control in diabetics: *I. Semin Dial* 1993; 6:392.
- **Dikow, R, Ritz, E.** Cardiovascular complications in the diabetic patient with renal disease: An update in 2003. *Nephrol Dial Transplant* 2003; 18:1993.

- **Doublier, S, Salvidio, G, Lupia, E, et al.** Nephlin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. *Diabetes* 2003; 52:1023.
- **Douglas, K, O'Malley, PG, Jackson, JL.** Meta-analysis: the effect of statins on albuminuria. *Ann Intern Med* 2006; 145:117.
- **Dworkin, LD, Gong, R, Tolbert, E, et al.** Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. *Kidney Int* 2004; 65:409.
- **Earle, K, Viberti, GC.** Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. *Kidney Int* 1994; 45:434.
- **Eds Cecka JM and Terasaki PI.** UCLA Immunogenetics Center, 2003. *Clinical Transplants* 2002
- Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. **The Diabetes Control and Complications (DCCT) Research Group.** *Kidney Int* 1995; 47:1703.
- **Ejerblad, E, Foreb, CM, Lindblad, P, et al.** Obesity and risk for chronic renal failure. *J Am Soc Nephrol* 2006; 17:1695.
- **Emoto, N, Yanagisawa, M.** Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. *J Biol Chem* 1995; 270:15262.
- **Engerman, RL, Kern, TS, Garment, MB.** Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. *J Diabetes Complications* 1993; 7:241
- **Epstein, M, Campese, VM.** Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. *Am J Kidney Dis* 2005; 45:2.
- **Epstein, M, Sowers, JR.** *Diabetes mellitus and hypertension.* *Hypertension* 1992; 19:403.

- **Epstein, M, Williams, GH, Weinberger, M, et al.** Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. *Clin J Am Soc Nephrol* 2006; 1:940.
- **Esnault, VL, Ekhlās, A, Delcroix, C et al.** Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. *J Am Soc Nephrol* 2005; 16:474.
- **Esposito, C, Parrilla, B, De Mauri, A, et al.** Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. *Kidney Int* 2005; 67:2143.
- **Facchini, FS, Hollenbeck, CB, Jeppesen, J, et al.** Insulin resistance and cigarette smoking. *Lancet* 1992; 339:1128.
- **Fellstrom, BC, Holdaas, H, Jardine, AG.** Why do we need a statin trial in hemodialysis patients?. *Kidney Int Suppl* 2003; :S204.
- **Ferder, L, Daccordi, H, Martello, M, et al.** Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. *Hypertension* 1992; 19:II237.
- **Finne, P, Reunanen, A, Stenman, S, et al.** Incidence of end-stage renal disease in patients with type 1 diabetes. *JAMA* 2005; 294:1782.
- **Fioretto, P, Mauer, SM, Bilous, RW, et al.** Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. *Lancet* 1993; 342:1193.
- **Fioretto, P, Steffes, MW, Sutherland, DE, et al.** Reversal of lesions of diabetic nephropathy after pancreas transplantation. N *Engl J Med* 1998; 339:69.
- **Fioretto, P, Sutherland, DE, Najafian, B, Mauer, M.** Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. *Kidney Int* 2006; 69:907.
- **Fliser, D, Wagner, KK, Loos, A, et al.** Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. *J Am Soc Nephrol* 2005; 16:1135.
- **Forbes, JM, Soulis, T, Thallas, V, et al.** Renoprotective effects of a novel inhibitor of advanced glycation. *Diabetologia* 2001; 44:108.

- **Freedman, BI, Wuerth, JP, Cartwright, K, et al.** Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). *Control Clin Trials* 1999; 20:493.
- **Freeman, SL, O'Brien, PC, Rizza, RA.** Use of human ultralente as the basal insulin component in treatment of patients with IDDM. *Diabetes Res Clin Pract* 1991; 12:187.
- **Gaber, L, Walton, C, Brown, S, Bakris, G.** Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. *Kidney Int* 1994; 46:161.
- **Gaede, P, Vedel, P, Larsen, N, et al.** Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003; 348:383.
- **Gambara, V, Mecca, G, Remuzzi, G, Bertani, T.** Heterogeneous nature of renal lesions in type II diabetes. *J Am Soc Nephrol* 1993; 3:1458.
- **Gassel, M, Breitenlechner, CB, Konig, N, et al.** The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A. *J Biol Chem* 2004; 279:23679.
- **Gaston, RS, Basadonna, G, Cosio, FG, et al.** Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. *Am J Kidney Dis* 2004; 44:529.
- **Giardino, I, Fard, AK, Harchell, DL, Brownlee, M.** Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. *Diabetes* 1998; 47:1114.
- **Goddard, J, Eckhart, C, Johnston, NR, et al.** Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. *J Am Soc Nephrol* 2004; 15:2601.
- **Goddard, J, Johnston, NR, Hand, MF, et al.** Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of

selective and combined endothelin receptor blockade. *Circulation* 2004; 109:1186.

- **Goldberg, T, Cai, W, Peppas, M, et al.** Advanced glycoxidation end products in commonly consumed foods. *J Am Diet Assoc* 2004; 104:1287.
- **Greene, DA, Lattimer, SA, Sima, AA.** Sorbitol, phosphoinositides, and sodium-potassium ATPase in the pathogenesis of diabetic complications. *N Engl J Med* 1987; 316:599.
- **Griffin, KA, Picken, MM, Bakris, GL, Bidani, AK.** Class differences in the effects of calcium channel blockers in the rat remnant kidney model. *Kidney Int* 1999; 55:1849.
- **Guan, Y.** Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. *J Am Soc Nephrol* 2004; 15:2801
- **Guan, Y, Hao, C, Cha, DR, et al.** Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. *Nat Med* 2005; 11:861
- **Haire-Joshu, D, Glasgow, RE, Tibbs, TL.** Smoking and diabetes. *Diabetes Care* 1999; 22:1887.
- **Han, SY, Kim, CH, Kim, HS, et al.** Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. *J Am Soc Nephrol* 2006; 17:1362.
- **Haneda, M, Kikkawa, R, Sugimoto, T, et al.** Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. *J Diabetes Complications* 1995; 9:246.
- **Hansen, HP, Tauber-Lassen, E, Jensen, BR, Parving, HH.** Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. *Kidney Int* 2002; 62:220.
- **Harris, RD, Steffes, MW, Bilous, RW, et al.** Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. *Kidney Int* 1991; 40:107.

- **Hartog, JW, Smit, AJ, van Son, WJ, et al.** Advanced glycation end products in kidney transplant patients: A putative role in the development of chronic renal transplant dysfunction. *Am j Kidney Dis 2004; 43:966..*
- **Hasslacher, C.** Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. *Diabetes Care 2003; 26:886..*
- **Hayashi, K, Epstein, M, Loutzenheiser, R, Forster, H.** Impaired myogenic responsiveness of afferent arteriole in streptozotocin-induced diabetic rats: Role of eicosanoid derangements. *J Am Soc Nephrol 1992; 2:1578.*
- **Hebert, LA, Bain, RP, Verme, D, et al.** Remission of nephrotic range proteinuria in type I diabetes. *Kidney Int 1994; 46:1688.*
- **Heilig, CW, Concepcion, LA, Riser, BL, et al.** Overexpression of glucose transporters in mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. *J Clin Invest 1995; 96:1802.*
- **Hilgers, KF, Veelken, R.** Type 2 Diabetic Nephropathy: Never too Early to Treat?. *J Am Soc Nephrol 2005; 16:574.*
- **Hohenstein, B, Hausknecht, B, Boehmer, K, et al.** Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. *Kidney Int 2006; 69:1654.*
- **Hosoda, K, Nakao, K, Tamura, N, et al.** Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. *J Biol Chem 1992; 267:18797*
- **Hotta, N.** New concepts and insights on pathogenesis and treatment of diabetic complications: Polyol pathway and its inhibition. *Nagoya J Med Sci 1997; 60:89.*
- **Houlihan, CA, Allen, TJ, Baxter, AL, et al.** *Diabetes Care 2002; 25:663*
- **Hovind, P, Rossing, P, Tarnow, L, et al.** Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. *Kidney Int 2001; 60:277.*

- **Hovind, P, Rossing, P, Tarnow, L, et al.** Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001; 24:1972.
- <http://www.clinicaltrials.gov/ct/show/NCT00120328?order=1> (Accessed on December 18, 2006).
- **Hughes, TA, Gaber, AO, Amiri, HS, et al.** Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: *Effect of kidney and pancreas transplantation. Metabolism* 1994; 43:333.
- **Hypertension in Diabetes Study (HDS): I.** Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309.
- **Ichihara, A, Suzuki, F, Nakagawa, T, et al.** Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17:1950.
- **Initial results of the Protein Kinase C {beta} Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial.** The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Diabetes 2005; 54:2188.
- **Ishii, H, Jirouske, MR, Koya, D, et al.** Amelioration of vascular dysfunction in diabetic rats by an oral PKC β 2 inhibitor. Science 1996; 272:728.
- **Ismail, N, Becker, B, Strzelczyk, P, Ritz, E.** Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55:1.
- **Iso, K, Tada, H, Kuboki, K, Inokuchi, T.** Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications 2001; 15:241.
- **Jacobsen, P, Andersen, S, Jensen, BR, Parving, HH.** Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14:992.

- **Jacobsen, P, Andersen, S, Rossing, K, Jensen, BR.** Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. *Kidney Int* 2003; 63:1874.
- **Jafar, TH, Stark, PC, Schmid, CH, et al.** Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. *Kidney Int* 2001; 60:1131.
- **Jakus, V, Rietbrock, N.** Advanced glycation end-products and the progress of diabetic vascular complications. *Physiol Res* 2004; 53:131.
- **Janssen, B, Hohenadel, D, Brinkkoetter, P, et al.** Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNBP1. *Diabetes* 2005; 54:2320.
- **Joy, MS, Cefalu, WT, Hogan, SL, Nachman, PH.** Long-term glycemic control measurements in diabetic patients receiving hemodialysis. *Am J Kidney Dis* 2002; 39:297.
- **Jukema, JW, Smets, YF, van der, Pijl JW, et al.** Impact of simultaneous pancreas and kidney transplantation on progression of coronary atherosclerosis in patients with end-stage renal failure due to type 1 diabetes. *Diabetes Care* 2002; 25:906.
- **K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.** *Am J Kidney Dis* 2005; 4(Suppl 3):S1.
- **Kalousova, M, Zima, T, Tesar, V, et al.** Advanced glycation end products in clinical nephrology. *Kidney Blood Press Res* 2004; 27:18.
- **Kassab, JP, Guillot, R, Andre, J, et al.** Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional, and ultrastructural studies. *Biochem Pharmacol* 1994; 48:1003.
- **Katayama, K, Nomura, S, Ishikawa, H, et al.** Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. *Kidney Int* 2006; 70:151.
- **Katz, H, Homan, M, Velosa, J, et al.** Effects of pancreas transplantation on postprandial glucose metabolism. *N Engl J Med* 1991; 325:1278.

- **Katz, HH, Nguyen, TT, Velosa, JA, et al.** Effects of systemic delivery of insulin on plasma lipids and lipoprotein concentrations in pancreas transplant recipients. *Mayo Clin Proc* 1994; 69:231.
- **Kelly, DJ, Chanty, A, Gow, RM, et al.** Protein kinase C β inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. *J Am Soc Nephrol* 2005; 16:1654.
- **Kendall, DM, Rooney, DP, Smets, YF, et al.** Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. *Diabetes* 1997; 46:249.
- **Kohler, KA, McClellan, WM, Ziemer, DC, et al.** Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. *Am J Kidney Dis* 2000; 36:903.
- **Komander, D, Kular, GS, Schuttelkopf, AW, et al.** Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. *Structure (Camb)* 2004; 12:215.
- **Koya, D, Lee, IK, Ishii, H, et al.** Prevention of glomerular dysfunction in diabetic rats by treatment of d-alpha-tocopherol. *J Am Soc Nephrol* 1997; 8:426
- **Krolewski, AS, Warram, JH, Christlieb, AR.** Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. *Kidney Int Suppl* 1994; 45:S125.
- **Krolewski, AS.** *Genetics of diabetic nephropathy: Evidence for major and minor gene effects.* *Kidney Int* 1999; 55:1582.
- **Krolewski, M, Eggers, PW, Warram, JH.** Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. *Kidney Int* 1996; 50:2041.
- **Kunz, R, Bork, JP, Fritsche, L, et al.** Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review. *J Am Soc Nephrol* 1998; 9:1653.

- **Kuramoto, N, Lizuka, T, Ito, H, et al.** Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. *Am J Kidney Dis 1999; 33:276.*
- **Lajer, M, Tarnow, L, Fleckner, J, et al.** Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients. *Diabet Med* 2004; 21:867. Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients. *Diabet Med 2004; 21:867.*
- **Leslie, RD.** United Kingdom prospective diabetes study (UKPDS): what now or so what?. *Diabetes Metab Res Rev 1999; 15:65.*
- **Leung, WY, So, WY, Tong, PC, et al.** The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. *Nephrol Dial Transplant 2004; 19:2519.*
- **Lewis, EJ, Hunsicker, LG, Bain, RP, Rohde, RD.** The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. *N Engl J Med 1993; 329:1456*
- **Lin, CL, Wang, JY, Huang, YT, et al.** Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. *J Am Soc Nephrol 2006; 17:2812.*
- **Lin, SL, Chen, RH, Chen, YM, et al.** Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. *J Am Soc Nephrol 2005; 16:2702.*
- **Lindholm, LH, Ibsen, H, Dahlof, B, et al.** Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet 2002; 359:1004.*
- **Locatelli, F, Pozzoni, P, Del Vecchio, L.** Renal replacement therapy in patients with diabetes and end-stage renal disease. *J Am Soc Nephrol 2004; 15 Suppl 1:S25.*
- **Lowrie, EG, Lew, NL, Huang, WH.** Race and diabetes as death predictors in hemodialysis patients. *Kidney Int Suppl 1992; 38:S22.*

- **Luzi, L, Secchi, A, Facchini, F, et al.** Reduction of insulin resistance by combined kidney-pancreas transplantation in type 1 (insulin-dependent) diabetic patients. *Diabetologia* 1990; 33:549.
- **Mak, RH.** Impact of end-stage renal disease and dialysis on glycemic control. *Semin Dial* 2000; 13:4.
- **Mak, RH, DeFronzo, RA.** Glucose and insulin metabolism in uremia. *Nephron* 1992; 61:377.
- **Makita, Z, Bucala, R, Rayfield, EJ, et al.** Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. *Lancet* 1994; 343:1519.
- **Manto, A, Cotroneo, P, Marra, G, et al.** Effect of intensive treatment on diabetic nephropathy in patients with type I diabetes. *Kidney Int* 1995; 47:231.
- **Mauer, SM, Goetz, FC, McHugh, LE, et al.** Long-term study of normal kidneys transplanted into patients with type I diabetes. *Diabetes* 1989; 38:516.
- **MC GOWAN ET AL** *BR J PHARMACOL* 133:68,2001. *JASN* 2000.
- **McAuliffe, AV, Brooks, BA, Fisher, EJ, et al.** Administration of ascorbic acid and an aldose reductase inhibitor (Tolrestat) in diabetes: Effect on urinary albumin excretion. *Nephron* 1998; 80:277.
- **McCarty, MF.** Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. *Med Hypotheses* 2003; 60:634.
- **Mogensen, CE, Hansen, KW, Pedersen, MM, Christensen, CK.** Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. *Diabetes Care* 1991; 14 Suppl 4:13.
- **Mogensen, CE, Neldam, S, Tikkanen, I, et al.** Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ* 2000; 321:1440.

- **Morales, E, Valero, MA, Leon, M, et al.** Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. *Am J Kidney Dis 2003; 41:319.*
- **Morcos, M, Borcea, V, Isermann, B, et al.** Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: An exploratory study. *Diabetes Res Clin Pract 2001; 52:175.*
- **Motomiya, Y, Oyama, N, Iwamoto, H, et al.** N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. *Kidney Int 1998; 54:1357.*
- **Mueller, PW, Rogus, JJ, Cleary, PA, et al.** Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. *J Am Soc Nephrol 2006; 17:1782.*
- **Myers, BD, Nelson, RG, Williams, GW, et al.** Glomerular function in Pima Indians with noninsulin-dependent diabetes mellitus of recent onset. *J Clin Invest 1991; 88:524.*
- **Nagai, T, Imamura, M, Iizuka, K, et al.** Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. *Diabetes Res Clin Pract 2003; 59:191*
- **Nagai, Y, Yao, L, Kobori, H, et al.** Temporary Angiotensin II Blockade at the Prediabetic Stage Attenuates the Development of Renal Injury in Type 2 Diabetic Rats. *J Am Soc Nephrol 2005; 16:703.*
- **Nakamura, S, Makita, Z, Ishikawa, S, et al.** Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. *Diabetes 1997; 46:895.*
- **Nakao, N, Yoshimura, A, Morita, H, et al.** Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. *Lancet 2003; 361:117.*

- **Nathan, DM, Cleary, PA, Backlund, JY, et al.** Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005; 353:2643.
- **Navarro, JF, Mora, C, Muros, M, Garcia, J.** Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. *J Am Soc Nephrol* 2005; 16:2119.
- **Nelson, CB, Port, FK, Wolfe, RA, Guire, KE.** The association of diabetic status, age and race to withdrawal from dialysis. *J Am Soc Nephrol* 1994; 4:1608.
- **Nelson, RG, Knowler, WC, Pettitt, DJ, et al.** Diabetic kidney disease in Pima Indians. *Diabetes Care* 1993; 16:335.
- **Newman, DJ, Mattock, MB, Dawnay, AB, et al.** Systematic review on urine albumin testing for early detection of diabetic complications. *Health Technol Assess* 2005; 9:iii. 5.
- **Nguyen, G.** Renin/prorenin receptors. *Kidney Int* 2006; 69:1503.
- **Nishimura, C, Saito, T, Ito, T, et al.** High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. *Diabetologia* 1994; 37:
- **Nowack, R, Raum, E, Blum, W, Ritz, E.** Renal hemodynamics in recent-onset type II diabetes. *Am J Kidney Dis* 1992; 20:342.
- **Okopien, B, Krysiak, R, Herman, ZS.** Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. *J Clin Endocrinol Metab* 2006; 91:1770.
- **Oldfield, MD, Bach, LA, Forbes, JM, et al.** Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). *J Clin Invest* 2001; 108:1853.
- **Oomichi, T, Emoto, M, Tabata, T, et al.** Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. *Diabetes Care* 2006; 29:1496.

- **Ozsoy, RC, Koopman, MG, Kastelein, JJ, Arisz, L.** The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis. *Clin Nephrol* 2005; 63:245.
- **Panichi, V, Paoletti, S, Mantuano, E, et al.** In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. *Nephrol Dial Transplant* 2006; 21:337.
- **Park, L, Raman, KG, Lee, KJ, et al.** Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. *Nat Med* 1998; 4:1025.
- **Park, SH, Choi, HJ, Lee, JH, et al.** High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1. *Kidney Int* 2001; 59:1695.
- **Parving, HH, Hommel, E, Jensen, BR, Hansen, HP.** Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patient *Kidney Int* 2001; 60:228
- **Parving, HH, Hommel, E, Mathiesen, E, et al.** Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. *Br Med J* 1988; 296:156.
- **Passariello, N, Sepe, J, Marrazzo, G, et al.** Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. *Diabetes Care* 1993; 16:789.
- **Pavkov, Me, Bennett, PH, Knowler, WC, et al.** Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. *JAMA* 2006; 296:421.
- **Pavkov, ME, Knowler, WC, Bennett, PH, et al.** Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. *Kidney Int* 2006; 70:1840.
- **Pedersen, MM, Christiansen, JS, Mogensen, CE.** Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 months of aldose reductase inhibition. *Diabetes* 1991; 40:527.

- **Pettersson-Fernholm, K, Frojdo, S, Fagerudd, J, et al.** The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. *Kidney Int* 2006; 69:1880.
- **Pettitt, DJ, Saad, MF, Bennett, PH, et al.** Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1990; 33:438.
- **Portero-Otin, M, Pamplona, R, Bellmunt, MJ, et al.** Advanced glycation end product precursors impair epidermal growth factor receptor signaling. *Diabetes* 2002; 51:1535.
- **Tracey, KJ, Cerami, A.** Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilation in experimental diabetes. *J Clin Invest* 1991; 87:432.
- **Rachmani, R, Slavachevsky, I, Amit, M, et al.** The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. *Diabet Med* 2004; 21:471.
- **Rahbar, S, Natarajan, R, Yerneni, K, et al.** Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. *Clin Chim Acta* 2000; 301:65.
- **Raj, DS, Choudhury, D, Welbourne, TC, Levi, M.** Advanced glycation end products: A nephrologist's perspective. *Am J Kidney Dis* 2000; 35:365.
- **Ramana, KV, Friedrich, B, Tammali, R, et al.** Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. *Diabetes* 2005; 54:81.
- **Reichard, P, Nilsson, BY, Rosenqvist, U.** The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *N Engl J Med* 1993; 329:304.

- **Reichard, P, Nilsson, BY, Rosenqvist, U.** The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *N Engl J Med* 1993; 329:304.
- **Ritz, E, Orth, SR.** Nephropathy in patients with type 2 diabetes mellitus. *N Engl J Med* 1999; 341:1127
- **Robertson, RP.** Consequences on beta-cell function and reserve after long-term pancreas transplantation. *Diabetes* 2004; 53:633.
- **Robison, WG Jr, Tillis, TN, Laver, N, Kinoshita, JH.** Diabetesrelated histopathologies of the rat retina prevented with an aldose reductase inhibitor. *Exp Eye Res* 1990; 50:355.
- **Rodriguez-Moran, M, Gonzalez-Gonzalez, G, Bermudez-Barba, MV, et al.** Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial. *Clin Nephrol* 2006; 66:3.
- **Rosca, MG, Mustata, TG, Kinter, MT, et al.** Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. *Am J Physiol Renal Physiol* 2005; 289:f420.
- **Rossing, P, Rossing, K, Jacobsen, P, Parving, HH.** Unchanged incidence of diabetic nephropathy in IDDM patients. *Diabetes* 1995; 44:739.
- **Rudberg, S, Persson, B, Dahlquist, G.** Increased glomerular filtration rate as a predictor of diabetic nephropathy An 8-year prospective study. *Kidney Int* 1992; 41:822.
- **Ruggenenti, P, Fassi, A, Ilieva, AP, et al.** Preventing microalbuminuria in type 2 diabetes. *N Engl J Med* 2004; 351:1941.
- **Ruggenenti, P, Gambarà, V, Perna, A, et al.** The nephropathy of non-insulin-dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. *J Am Soc Nephrol* 1998; 9:2336.

- **Ruggenti, P, Perna, A, Ganeva, M, et al.** Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial. *J Am Soc Nephrol* 2006; 17:3472.
- **Saiki, A, Nagayama, D, Ohhira, M, et al.** Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. *Int J Obes (Lond)* 2005; 29:1115.
- **Satko, SG, Langefeld, CD, Daeihagh, P, et al.** Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy. *Am J Kidney Dis* 2002; 40:489.
- **Schmidt, K, Pesce, C, Liu, Q, et al.** Large glomerular size in Pima Indians: Lack of change in diabetic nephropathy. *J Am Soc Nephrol* 1992; 3:229.
- **Schrrier, RW, Estacio, RO, Esler, A, Mehler, P.** Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy, and strokes. *Kidney Int* 2002; 61:1086.
- **Schwedler, S, Verbeke, P, Bakala, H, et al.** N-phenacylthizolium bromide (PTB) decreases renal AGE levels and increases urinary AGE excretion without ameliorating diabetic nephropathy in C57BL/6 mice. *J Am Soc Nephrol (abstract)* 1998; 9:641A.
- **Scondotto, G, Agnelli, G, et al.** Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. *Thromb Haemost* 2002; 87:947. Khan, KN, Stanfield, KM, Harris, RK, Baron, DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. *Ren Fail* 2001; 23:321
- **Selgas, R.** Comparative study of two different routes for insulin administration in CAPD patients: A multicenter study. *Adv Perit Dial* 1988; 4:126.
- **Sensi, M, Pricci, F, Andreani, D, DiMario, U.** Advanced nonenzymatic glycation end products (AGE): Their relevance to aging and the pathogenesis of late diabetic complications. *Diabetes Res* 1991; 16:

- **Shah, VO, Scavini, M, Nikolic, J, et al.** Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. *J Clin Endocrinol Metab* 1998; 83:2886.
- **Sharma, K, Eltayeb, BO, McGowan, TA, et al.** Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin- dependent diabetic patients. *Am J Kidney Dis* 1999; 34:818.
- **Shiba, T, Inoguchi, T, Sportsman, JR, et al.** Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. *Am J Physiol* 1993; 265:E783.
- **Shichiri, M, Kishikawa, H, Ohkubo, Y, Wake, N.** Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000; 23 Suppl 2:B21.
- **Shimizu, T, Kuroda, T, Hata, S, et al.** Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. *Kidney Int* 1998; 54:99.
- **Singh, AK, Mo, W, Dunea, G, Arruda, JA.** Effect of glycated proteins on the matrix of glomerular epithelial cells. *J Am Soc Nephrol* 1998; 9:802.
- **Skillman, TG, Feldman, JM.** The pharmacology of sulfonylureas. *Am J Med* 1981; 70:361.
- **Smith, AC, Toto, R, Bakris, GL.** Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. *Kidney Int* 1998; 54:889.
- **Smith, SR, Svetkey, LP, Dennis, VW.** Racial differences in the incidence and progression of renal diseases. *Kidney Int* 1991; 40:815.
- **Snyder, RW, Berns, JS.** Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. *Semin Dial* 2004; 17:365.
- **Soma, J, Sato, K, Saito, H, Tsuchiya, Y.** Effect of tranilast in early-stage diabetic nephropathy. *Nephrol Dial Transplant* 2006; 21:2795.

- **Song, JH, Cha, SH, Lee, HJ, et al.** Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. *Nephrol Dial Transplant* 2006; 21:683.
- **Soulis, T, Cooper, ME, Vranes, D, et al.** Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. *Kidney Int* 1996; 50:627.
- **Soulis-Liparota, T, Cooper, ME, Dunlop, M, Jerums, G.** The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. *Diabetologia* 1995; 38:387.
- **Steffes, MW.** Affecting the decline of renal function in diabetes mellitus. *Kidney Int* 2001; 60:378.
- **Strippoli, GF, Craig, M, Schena, FP, Craig, JC.** Antihypertensive agents for primary prevention of diabetic nephropathy. *J Am Soc Nephrol* 2005; 16:3081
- **Suissa, S, Hutchinson, T, Brophy, JM, Kezouh, A.** ACE-inhibitor use and the long-term risk of renal failure in diabetes. *Kidney Int* 2006; 69:913.
- **Sung, SH, Ziyadeh, FN, Wang, A, et al.** Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. *J Am Soc Nephrol* 2006; 17:3093.
- **Suzuki, H, Shimosegawa, T, Ohara, S, Toyota, T.** Epalrestat prevents the decrease in gastric mucosal blood flow and protects the gastric mucosa in streptozotocin diabetic rats. *J Gastroenterol* 1999; 34:172.
- **Svensson, M, Nystrom, L, Schon, S, Dahlquist, G.** Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease: a nationwide population-based study. *Diabetes Care* 2006; 29:538.
- **Tanaka, S, Avigad, G, Brodsky, B, Eikenberry, EF.** Glycation induces expansion of the molecular packing of collagen. *J Mol Biol* 1988; 203:495

- **Tang, SC, Leung, JC, Chan, LY, et al.** Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor- γ agonist. *J Am Soc Nephrol* 2006; 17:1633.
- **Tanji, N, Markowitz, GS, Fu, C, et al.** Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. *J Am Soc Nephrol* 2000; 11:1656.
- **Tapp, RJ, Shaw, JE, Zimmet, PZ, et al.** Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). *Am J Kidney Dis* 2004; 44:792.
- **Tascona, DJ, Morton, AR, Toffelmire, EB, et al.** Adequacy of glycemic control in hemodialysis patients with diabetes. *Diabetes Care* 2006; 29:2247.
- **The Diabetes Control and Complications Trial Research Group.** The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329:977.
- **The Diabetes Control and Complications Trial Research Group.** The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329:977.
- **The Epidemiology of Diabetes Interventions and Complications (EDIC) study.** Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy *JAMA* 2003; 290:2159.
- **Tilton, RG, Change, K, Hasan, KS, et al.** Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation endproduct formation. *Diabetes* 1993; 42:221.
- **Tomlinson, DR, Stevens, EJ, Diemel, LT.** Aldose reductase inhibitors and their potential for the treatment of diabetic complications. *Trends Pharmacol Sci* 1994; 15:293.

- **Tonelli, M, Isles, C, Craven, T, et al.** Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. *Circulation* 2005; 112:171.
- **Tonolo, G, Velussi, M, Brocco, E, et al.** Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. *Kidney Int* 2006; 70:177.
- **Trevisan, R, Viberti, G.** Genetic factors in the development of diabetic nephropathy. *J Lab Clin Med* 1995; 126:342.
- **Tsilibary, EC, Charonis, AS, Reger, LA, et al.** The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. *J Biol Chem* 1988; 263:4302.
- **Tsuchida, K, Makita, Z, Yamagishi, S.** Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. *Diabetologia* 1999; 42:579.
- **Tuttle, KR, Anderson, PW.** A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. *Am J Kidney Dis* 2003; 42:456.
- **Tuttle, KR, Bakris, GL, Toto, RD, et al.** The effect of ruboxistaurin on nephropathy in type 2 diabetes. *Diabetes Care* 2005; 28:2686.
- **Tuttle, KR, Bruton, JL, Perusek, MC, et al.** Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. *N Engl J Med* 1991; 324:1626.
- **Tuttle, KR, Bruton, JL.** Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. *Kidney Int* 1992; 42:167.
- **Tuttle, KR, Johnson, EC, Cooney, SK, et al.** Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. *Kidney Int* 2005; 67:953.
- **Tzamaloukas, AH.** The use of glycosylated hemoglobin in dialysis patients. *Semin Dial* 1998; 11:143.

- **Tzamaloukas, AH, Friedman, EA.** Diabetes. In: *Handbook of Dialysis, 3rd ed, Daugirdas, JT, Blake, PG, Ing, TS (Eds), Lippincott, Williams, and Wilkins, 2001, pp. 453-465.*
- **Tzamaloukas, AH, Oreopoulos, DG.** Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: A review. In: *Adv Peritoneal Dial, Vol 7, Khanna, R, Nolph, KD, Prowant, B, et al (Eds), University of Toronto Press, 1991, pp 81-85.*
- **United States Renal Data System.** Excerpts from the USRDS 2005 annual data report: Atlas of end-stage renal disease in the United States. *Am J Kidney Dis 2006; 47(Suppl 1):S1.*
- **Van den Hoven, MJ, Rops, AL, Bakker, MA, et al.** Increased expression of heparanase in overt diabetic nephropathy. *Kidney Int 2006; Jan 11.*
- **Van den, Meiracker AH, Baggen, RG, Pauli, S, et al.** Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. *J Hypertens 2006; 24:2285.*
- **Vasan, S, Zhang, X, Zhang X, et al.** An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. *Nature 1996; 382:275.*
- **Verhulst, A, D'Haese, PC, De Broe, ME.** Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. *J Am Soc Nephrol 2004; 15:2249.*
- **Viberti G, Mogensen CE, Groop LC, et al.** Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. *JAMA 1994; 271:27*
- **Vlassara, H, Cai, W, Crandall, J, et al.** Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. *Proc Natl Acad Sci USA 2002; 26:99.*
- **Vlassara, H, Fuh, H, Makita, Z, et al.** Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. *Proc Natl Acad Sci U S A 1992; 89:12043.*

- **Vlassara, H. Protein glycation in the kidney:** Role in diabetes and aging. *Kidney Int* 1996; 49:1795.
- **Vlassara, H.** Serum advanced glycosylation end products: A new class of uremic toxins? *Blood Purif* 1994; 12:54.
- **Voziyan, PA, Hudson, BG.** Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. *Cell Mol Life Sci* 2005; 62:1671.
- **Wada, R, Nishizawa, Y, Yagihashi, N, et al.** Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. *Eur J Clin Invest* 2001; 31:513.
- **Wang, PH, Lau, J, Chalmers, TC.** Meta-analysis of effects of intensive blood glucose control on later complications of type I diabetes. *Lancet* 1993; 341:1306
- **Wang, S, de Caestecker, M, Kopp, J, et al.** Renal bone morphogenetic protein-7 protects against diabetic nephropathy. *J Am Soc Nephrol* 2006; 17:2504.
- **Wendt, T, Tanji, N, Guo, J, Hudson, BI.** Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy. *J Am Soc Nephrol* 2003; 14:1383.
- **Whittier, F, Spinowitz, B, Wuerth, JP, Cartwright, K.** Pimagidine (PG) safety profile in patients with Type I diabetes mellitus (DM). *J Am Soc Nephrol* 1999; 10:184A.
- **WHO Pharmaceutical Newsletter** N° 3-4, 12:1997
- **Williams, ME, Lacson, E Jr, Teng, M, et al.** Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. *Kidney Int* 2006; 70:1503.
- **Williams, ME, Tuttle, KR.** The next generation of diabetic nephropathy therapies: an update. *Adv Chronic Kidney Dis* 2005; 12:212.
- **Wilmer, WA, Hebert, LA, Lewis, EJ, et al.** Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. *Am J Kidney Dis* 1999; 34:308.

- **Wolf, G, Ziyadeh, FN.** Molecular mechanisms of diabetic renal hypertrophy. *Kidney Int* 1999; 56:393.
- **Wu, MJ, Wen, MC, Chiu, YT, et al.** Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. *Kidney Int* 2006; 69:2029.
- **Yamagishi, S, Nakamura, K, Takeuchi, M.** Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders. *Med Hypotheses* 2005; 65:392.
- **Yamamoto, Y, Kato, I, Doi, T, et al.** Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. *J Clin Invest* 2001; 108:261.
- **Yang, CW, Vlassara, H, Peten, EP, et al.** Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. *Proc Natl Acad Sci U S A* 1994; 91:9436.
- **Yoshikawa, M, Shimada, H, Nishida, N, Li, Y.** Antidiabetic principles of natural medicines. II. Aldose reductase and alpha-glucosidase inhibitors from Brazilian natural medicine, the leaves of *Myrcia multiflora* DC. (Myrtaceae): structures of myrciacitrins I and II and myrciaphenones A and B. *Chem Pharm Bull (Tokyo)* 1998; 46:113.
- **Zeier, M, Schwenger, V, Deppisch, R, et al.** Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?. *Kidney Int* 2003; 63:298
- **Zeller, K, Whittaker, E, Sullivan, L, et al.** Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. *N Engl J Med* 1991; 324:78.
- **Zhang, Z, Shahinfar, S, Keane, WF, et al.** Importance of baseline distribution of proteinuria in renal outcomes trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. *J Am Soc Nephrol* 2005; 16:1775.
- **Zhao, HL, Tong, PC, Lai, FM, et al.** Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients. *Diabetes*. 2004; 53:2984

- **Ziyadeh, FN, Fumo, P, Rodenberger, CH, et al.** Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1(IV) in glomerular mesangial cells. *J Diabetes Complications* 1995; 9:255.
- **Michael Brownlee.** Biochemistry and molecular cell biology of diabetic complications . *Nature* 2001 414, 813-820.
- **David R. Tomlinson & Natalie J. Gardiner .** Glucose neurotoxicity
Nature Reviews Neuroscience 9, January 2008 , 36-45
- **Lewis, EJ, Hunsicker, LG, Bain, RP, Rohde, RD,** ACE inhibitor slows progression of diabetic nephropathy, *N Engl J Med* 1993; 329:1456.
- **Clark, CM Jr, Lee, DA,** AGE production and possible inhibition by aminoguanidine . *N Engl J Med* 1995; 332:1210.
- **Klahr, S, Levey, AS, Beck, GJ, et al,** BP control preserves renal function in proteinuric patients, *N Engl J Med* 1994; 330:877.

Stratton, I. M., Adler, A. I., Neil, H. A. W., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., and Holman, R. Association of glycaemic with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ.* 2002 : 321, 405-412

Du X, Stocklauser Farber K, Rosen P. Generation of reactive oxygen . intermediates, activation of NF-kappaB, induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? *Free Radic. Biol. Med.* 1999; 27: 752–63

- o **Cohen N. D. and Shaw J. E.:** Diabetes: advances in treatment. *Internal Medicine Journal*, 2007 37(16), 383-388.
- o **Goran Miric et al.:** Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. *British Journal of Pharmacology* (2001) 133, 687-694.
- o **Gross GL, de Azevedo MJ, Silveiro SP, Canani LH,**

Caramori ML, and Zelmanovitz T.: Diabetic Nephropathy: Diagnosis, Prevention, and Treatment *Diabetes Care* 28:164-176, 2005.

o **Joost F.M. Lensen et al.:** Localization and Functional Characterization of Glycosaminoglycan Domains in the Normal Human Kidney as Revealed by Phage Display–Derived Single Chain Antibodies. *J Am Soc Nephrol* 16: 1279–1288, 2005.

o **Katherine R. Tuttle et al.:** The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. *DIABETES CARE, VOLUME 28, NUMBER 11, NOVEMBER 2005*.

o **Mealey B. L. and Ocampo G. L.:** Diabetes mellitus and periodontal disease. *Periodontology* 2000. 2007 44(1), 127-153.

o **Sonkodi s. and Mogyorósi A.:** Treatment of diabetic nephropathy with angiotensin II blockers. *Nephrol Dial Transplant* (2003) 18 [Suppl 5]: v21–v23.

o **Vicki Thallas-Bonke et al.:** Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase Dependent Pathway. *Diabetes* 53:2921-2930, 2004.

o **Zhang YW, Wu CY and Cheng JT.:** Merit of Astragalus polysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expressions of NFkappaB and IkappaB in renal cortex of streptozotocin-induced diabetic rats. *J Ethnopharmacol.* 2007 Dec 3; 114(3):387-92.

-